Background Dengue fever is associated with many health complications and medical costs. Furthermore, there is currently no approved dengue antiviral medication or vaccine. Empiric evidence has suggested that patients who received supplemental methisoprinol therapy had faster recovery times and fewer complications.
D engue fever remains a serious public health concern in tropical regions as it continues to claim many lives year after year. The Philippines is known to be endemic for the four antigenic subtypes of dengue viruses, with no locality or social stratum spared from years age group. The World Health Organization risk from dengue. 3 Presently though, there is still no approved antiviral treatment for dengue. While there are protocols for effective standard supportive treatment with fluids and transfusions, the 'race for therapeutic modalities used by several health practitioners and even physicians who claim their effectiveness based on practice-based evidence. These include homeopathic remedies and trial-stage antiviral products, among others. Off-label use of methisoprinol for supplementary dengue treatment in the Philippines has only been testimonial in nature. 4 Methisoprinol is a synthetic complex of inosine and dimethylaminoisopropanol (as p-acetamidoben- 5 It belongs to the class of other antivirals, used as a direct-acting antiviral for the systemic treatment munomodulator. 6 Methisoprinol has already been proven effective in human and animal models either singly or in combination for many viral diseases. It is marketed in the Philippines for the following indications: subacute sclerosing panencephalitis measles, encephalitis, herpes zoster, herpes simplex labialis, hepatitis A, acute viral B hepatitis, herpes genitalis, as well as immunorestoration in conditions such as pre-acquired immune deficiency syndrome AIDS-related complex, neoplastic disease, anergy and .5 for dengue fever in Thailand, but no other studies have confirmed nor refuted its claims. We aimed to determine the effects of oral methisoprinol treatment on the clinical course of early phase dengue infection in pediatric patients and specifically, to establish the hemoconcentration, duration of confinement, and prevention of dengue complications. assessed to have severe dengue infection, critical or in the recovery phase of dengue fever, previously diagnosed with bleeding diathesis, platelet disorder or immunodeficiency disorder, previously ingested aspirin, ibuprofen or other antithrombotic medication unable to swallow oral medications (non per orem also secured verbally or in writing. Patients and their planned intervention, that placebo would be used and that improvement would be monitored through several laboratory tests. The medical risks associated with taking the medication were explained. A consent in English, Filipino, and Iluko. It was explained to them in the vernacular on the occasion that a patient could not understand these. The consent forms and research proposal were submitted and approved by the Bioethics Committee of the Saint Louis University Hospital of the Sacred Heart.
Methods
Patients were randomly assigned to either the methisoprinol group (syrup provided at a therapeutic the actual medication and placebo preparations had identical presentation without distinctive marks except for a letter coding (the identity of the products Assignment of treatment was done randomly with Random Allocation Software® ver 1.0 patients. The intervention was started immediately after laboratory confirmation of early dengue. Twelve also corresponded to the maximal period of viremia. Research assistants were responsible to administer, or supervise the administration of the correct intervention. A checklist for scheduling of dosages to fill. Clinical care, including other treatment such as intravenous fluids were at the discretion of the observation.
Patient profiles, diagnoses, classification, date and time of admission and discharge, vital signs and laboratory results were recorded in case record forms. Clinical history and significant examination findings were also recorded. Daily vital signs including temperature, obtained by aural digital thermometer results were logged on a daily basis. Laboratory determinations for serial hemoglobin, hematocrit, and platelet counts were done as clinically indicated, Inpatient laboratory determinations were done in the SLU-HSH Laboratory. Extent of hemoconcentration and thrombocytopenia variation was compared to normal values for age and sex. Fever clearance time, and duration of confinement, progression to dengue were noted accordingly.
The primary endpoint of the study was FCT, defined as the time from fever onset to the start of o C. Secondary endpoints mum hemoconcentration calculated as [(maximum normal hematocrit of age-and sex-matched popula-veloped DSS, were admitted to the ICU, transfused with blood products, and other complications such as bradyarrythmia or carditis, effusions, hepatitis or encephalitis.
there were 46 patients with dengue infection admitted are considered to be high-risk by the Department of Health. Ninety-six percent of cases treated were classified as uncomplicated dengue infection (all cases Supposing that half of these were in the early phase of dengue infection, then the ideal sample would be Data remained blinded until the database was finalized and ready for analysis. Statistical analysis was performed with SPSS Version 2.0. A two-sided P value eters. The null hypothesis was that isoprinosine had no effect on fever clearance, maximum hemoconcentration, leukopenia, thrombocytopenia, confinement duration, and development of dengue complications.
T-test were used to compare values between groups. There were some patients who had existing comorbidities while they were treated in the hospital, such as pneumonia, typhoid, and acute tonsillopharyngitis. Likewise, pre-admission anemia, baseline laboratory determination variability, and obesity may have also been present. These covariates thought to influence the time to resolution of fever, recovery, and laboratory results, were accounted for in the final model.
Results
children with dengue infection admitted to SLU Hospital. Having met the clinical inclusion criteria patients refused admission, one patient withdrew monitoring, and two patients did not meet the age to either the methisoprinol group or the placebo group suggesting that reliance on clinical symptoms coupled with timely laboratory determination are important to catch patients at the early stage of the disease. Three patients had pre-existing or concurrently treated comorbidities. Two patients had acute upper respiratory tract infections and one patient had alter the results.
age and gender, nor at admission baseline levels.
are summarized in Table 1 . developed fever afterwards during confinement, and confinement after a history of reported fever at home shortly before admission. Fevers seemed to clear faster in the placebo group than in the methisoprinol group, but this result was not statistically significant.
during confinement while medicating was recorded and compared to baseline values at the time of admission. The methisoprinol group had significantly lesser magnitude of WBC drop compared to the placebo group. Hence, methisoprinol reduced the during confinement was also recorded and compared to baseline values at admission. A smaller drop in platelet count was observed in the methisoprinol group than in the placebo group. Hence, methisoprinol reduced the anticipated thrombocytopenia by
Patients in the placebo group were hospitalized longer than the methisoprinol group, but this difference was not statistically significant.
The mean highest hematocrit level recorded methisoprinol group was higher than that of the placebo group. With regards to mean maximum hemoconcentration based on age-matched reference values, and baseline admission hematocrit level, or the last hematocrit taken after the patient was considered to be stable was not different between analysis in Figure 2 supports this lack of hematocrit difference between groups. Since R values in both consistent, predictable and significant relationship between medicating with either methisoprinol and hemoconcentration. All admitted patients were on IV fluid therapy and their treatment was according to protocols for dengue infection management. In addition, we also compared complications in the two groups. The outcomes are shown in Table 2 .
Discussion
Leukopenia usually precedes the onset of the critical phase of dengue and has been associated with severe disease. In our study, the WBC decrease in the methisoprinol group was 56% less than the anticipated WBC count decrease in the placebo group. Hence, if the theorized effect of methisoprinol were true, its immunostimulant role may have produced an increase in the overall WBC count, and effectively arrested or lessened the leukopenia and severity of effect can probably be explained based on its ability to normalize deficient or dysfunctional cell-mediated in turn, initiates T-lymphocyte maturation and differentiation as well as potentiation of induced lymphoproliferative responses in mitogen-or antigen-activated cells. Similarly, the drug has been shown to modulate T-lymphocyte and natural killer functions, and also to increase the number of IgG and complement surface markers. It increases cytokine vitro. It significantly increases endogenous IFNgamma secretion and decreases IL-4 production in vivo. 5 It has been shown to potentiate neutrophil, monocyte and macrophage chemotaxis and phagocytosis. As an antiviral, in vivo, methisoprinol enhances potentiation of depressed lymphocytic mRNA protein synthesis and translational ability,
achieved by yet to be clarified degrees of incorporation of inosine-mediated orotic acid into polyribosomes. It also inhibits of polyadenylic acid attachment to viral messenger RNA and engages in molecular reorganization of lymphocyte intramembrane plasma particles that result in a nearly threefold increase in density.
The effect of the test drug on platelet counts, on the other hand, was unexpected and the exact mechanism of methisoprinol action on the platelets cannot be explained by the existing literature.
The paucity of severe dengue complications is consistent with the anticipated absence of antibodydependent enhancement in primary infections. Since the population under study had mostly primary dengue infections, this scenario was anticipated. It is important to note, however, that our study is limited to the effects of methisoprinol in early dengue infection alone, and the full spectrum of its effect on later stages and more severe dengue cases was not assessed.
Methisoprinol was hypothesized to decrease fever duration, but this was not observed in our study. There were also no significant decreases in the recovery period or admission duration in our results. This may be explained by the fact that the number of hours of confinement is only, at best, an approximate reflection of the time of improvement or recovery of a dengue patient. Patients are not necessarily discharged at the time-point of clinical recovery. Patients may also be discharged earlier than others, based on the anticipated level of parental care and supervision at home or the amenability to followup. In our study, patients were not monitored after confinement, and no attempt was made to determine if or when laboratory parameters resumed to normal.
It is recommended that further studies be made in a hospital setting with more patient admissions, i.e., public hospitals in known dengue hotspots in the country and other Asian locales. We should allow for dedicated research assistants to help monitor homebound patients. Trials using different strengths (dosagare also recommended, as well as using in vitro studies antithrombocytopenic effects of the medication on the dengue virus in a local setting. reduce fever clearance time or length of hospital stay, nor do it diminish or prevent hemoconcentration or the development of complications in children with uncomplicated acute primary dengue infection. However, methisoprinol is observed to reduce leukopenia prinol could be used along with the standard, approved fluid and antipyretic therapy for dengue treatment. 
